EBT-107 is a CRISPR-based gene therapy that is being developed as a potential cure for chronic hepatitis B. The CRISPR/Cas gene editing system is formulated in lipid nanoparticles (LNPs) and is ...

Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...

Vir Biotechnology’s ‘functional cure’ combination therapy has failed to meet the efficacy endpoints in a Phase II trial in ...

Vir Biotechnology (NASDAQ:VIR) on Friday announced 24-week post-end-of-treatment data from a mid-stage trial for tobevibart ...

Vir Biotechnology, Inc. progresses HDV treatment with promising ECLIPSE program results. Click here to find out why VIR stock ...

Patients attending Medway Maritime Hospital's A&E will now be routinely tested for HIV and hepatitis unless they opt out. The ...

The "Hepatitis B - Pipeline Insight, 2025" drug pipelines has been added to ResearchAndMarkets.com's offering.This report outlays comprehensive insights of present clinical development scenario and ...

Address the issues of direct and indirect costs of testing and treatment to increase engagement by communities. Adopt testing ...

Managed cirrhosis encompasses a wide range of medical interventions and therapeutic strategies aimed at halting disease progression, reducing complications, and enhancing the quality of life of ...

A common medication used to treat HIV and hepatitis B may offer unexpected protection against Alzheimer's disease.